~~<i id='D13822A4B0'><strike id='D13822A4B0'><tt id='D13822A4B0'><pre id='D13822A4B0'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

knowledge

author：explore 2025-09-06 04:30:08 - browse：86191

JOHNSON & JOHNSON HEADQUARTERS — Daniel Hulshizer/AP

Eight months into his tenure, Johnson & Johnson’s R&D chief is putting a big emphasis on medicines for cancer, treatment-resistant depression, and autoimmune disease.

To sharpen that focus, R&D chief John Reed told STAT that the company is de-emphasizing two areas that have been mainstays for the drug and medical device giant: infectious disease and vaccines, as well as medicines targeting kidney disease and rare eye conditions.

The disclosures were made in an interview ahead of an investor meeting Reed is leading Tuesday aimed at generating excitement about the company’s research and development efforts.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

hotspot

focus

entertainment

MollyFergusonforSTATTheworld’slargesttechnologycompaniesareracingtobuildgenerativeAIintoeverycornero

WSS

A letter from the executive editor: STAT UnitedHealth investigation

FDA reorg will put new emphasis on investigations, sources say

Snackable artificial intelligence, expert AI, and the pharma industry

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

FDA reorg will put new emphasis on investigations, sources say

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

leisure time

knowledge

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

Ohio still needs to do more to protect the right to abortion

State Dept. review finds Biden bears some blame for Afghanistan failures

Stem cell treatment guidelines are released by FDA

Peter Hotez and the public health issue of online harassment

How state and local governments are sidelining science

Hepatitis C has a cure — but many Americans still lack access to it

A new House health package & hospitals’ new site

Duchenne breakthrough therapy leaves behind pioneering families

Type 2 diabetes prevention programs work at large scale: study

hotspot

Medical school prerequisites are outdated

'Make People Better': The CRISPR babies story you probably don't know

What drug price negotiations mean for Medicare Part D

Type 2 diabetes prevention programs work at large scale: study

NIH nominee Bertagnolli will get October confirmation hearing

After decades in use, heart stents finally beat placebo

hotspot

focus

focus

entertainment